dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Cárcel-Márquez, Jara |
dc.contributor.author | Carrera Vasconez, Caty |
dc.contributor.author | Llucià-Carol, Laia |
dc.contributor.author | Gallego-Fabrega, Cristina |
dc.contributor.author | Ribó Jacobi, Marc |
dc.contributor.author | Alvarez Sabin, José |
dc.contributor.author | Muiño, Elena |
dc.contributor.author | Cullell, Natalia |
dc.date.accessioned | 2022-03-22T14:22:40Z |
dc.date.available | 2022-03-22T14:22:40Z |
dc.date.issued | 2021-07 |
dc.identifier.citation | Muiño E, Cárcel-Márquez J, Carrera C, Llucià-Carol L, Gallego-Fabrega C, Cullell N, et al. RP11-362K2.2:RP11-767I20.1 Genetic Variation Is Associated with Post-Reperfusion Therapy Parenchymal Hematoma. A GWAS Meta-Analysis. J Clin Med. 2021 Jul;10(14):3137. |
dc.identifier.issn | 2077-0383 |
dc.identifier.uri | https://hdl.handle.net/11351/7238 |
dc.description | Hemorrhagic transformation; Parenchymal hematoma; Single nucleotide variants |
dc.description.abstract | Stroke is one of the most common causes of death and disability. Reperfusion therapies are the only treatment available during the acute phase of stroke. Due to recent clinical trials, these therapies may increase their frequency of use by extending the time-window administration, which may lead to an increase in complications such as hemorrhagic transformation, with parenchymal hematoma (PH) being the more severe subtype, associated with higher mortality and disability rates. Our aim was to find genetic risk factors associated with PH, as that could provide molecular targets/pathways for their prevention/treatment and study its genetic correlations to find traits sharing genetic background. We performed a GWAS and meta-analysis, following standard quality controls and association analysis (fastGWAS), adjusting age, NIHSS, and principal components. FUMA was used to annotate, prioritize, visualize, and interpret the meta-analysis results. The total number of patients in the meta-analysis was 2034 (216 cases and 1818 controls). We found rs79770152 having a genome-wide significant association (beta 0.09, p-value 3.90 × 10−8) located in the RP11-362K2.2:RP11-767I20.1 gene and a suggestive variant (rs13297983: beta 0.07, p-value 6.10 × 10−8) located in PCSK5 associated with PH occurrence. The genetic correlation showed a shared genetic background of PH with Alzheimer’s disease and white matter hyperintensities. In addition, genes containing the ten most significant associations have been related to aggregated amyloid-β, tau protein, white matter microstructure, inflammation, and matrix metalloproteinases. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Journal of Clinical Medicine;10(14) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Malalties cerebrovasculars - Tractament |
dc.subject | Reperfusió miocardíaca - Complicacions |
dc.subject.mesh | Stroke |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Reperfusion |
dc.subject.mesh | /adverse effects |
dc.title | RP11-362K2.2:RP11-767I20.1 Genetic Variation Is Associated with Post-Reperfusion Therapy Parenchymal Hematoma. A GWAS Meta-Analysis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/jcm10143137 |
dc.subject.decs | accidente cerebrovascular |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | reperfusión |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.3390/jcm10143137 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Muiño E, Cárcel-Márquez J, Llucià-Carol L] Stroke Pharmacogenomics and Genetics Group, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain. [Carrera C] Laboratori de Recerca Neurovascular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Gallego-Fabrega C] Stroke Pharmacogenomics and Genetics Group, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain. Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, 08025 Barcelona, Spain. [Cullell N] Stroke Pharmacogenomics and Genetics Group, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain. Stroke Pharmacogenomics and Genetics, Fundació MútuaTerrassa per la Docència i la Recerca, 08221 Terrassa, Spain. [Ribó M] Unitat d'Ictus, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Álvarez-Sabín J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Neurologia, Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 34300314 |
dc.identifier.wos | 000676723600001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |